Namratha Prabhu, MD
Interventional Pain Medicine · la Mesa, CANPI 1659717965
Payments from drug & device makers
Across 149 payments — averaging $35.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Spinal Simplicity, LLC$2K
- Abbott$2K
- Relievant Medsystems, Inc.$281
- Boston Scientific$238
- Nevro Corp.$154
- Curonix LLC$140
- plus $1K from 23 others
Across 1 payment — averaging $16.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Saluda Medical Americas, Inc.$16
What the payments were for
- Travel & lodging$4779%
- Food & beverage$3,35363%
- Education$1,49328%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Spinal Simplicity, LLC | 3 | $1,897 |
| Abbott | 72 | $1,581 |
| Relievant Medsystems, Inc. | 2 | $281 |
| Boston Scientific | 7 | $238 |
| Nevro Corp. | 5 | $154 |
| Curonix LLC | 2 | $140 |
| Scilex Pharmaceuticals Inc. | 8 | $122 |
| Collegium Pharmaceutical, Inc. | 6 | $100 |
| Stimwave Technologies Incorporated | 8 | $97 |
| AbbVie(2 entities) | 3 | $74 |
| Electronic Waveform Lab, Inc. | 2 | $66 |
| Hikma Pharmaceuticals USA | 3 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $54 |
| Lilly USA, LLC | 3 | $52 |
| Zyla Life Sciences, Inc. | 3 | $42 |
| Almatica Pharma LLC | 2 | $35 |
| Ipsen Biopharmaceuticals, Inc | 1 | $35 |
| Impel Pharmaceuticals Inc. | 2 | $34 |
| Amgen | 2 | $32 |
| Pfizer | 2 | $31 |
| Biodelivery Sciences International, Inc. | 2 | $31 |
| Bioventus LLC | 1 | $28 |
| Lundbeck LLC | 1 | $25 |
| GRT US Holding, Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Si-bone, Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| SPR Therapeutics, Inc | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HA MINUTEMAN G3-R$1,879
- Intracept$923
- Proclaim IPG$136
- GENERAL PAIN MANAGEMENT$123
How this compares
$5,322 in reported general payments places this provider in the 60th percentile of 188 interventional pain medicine providers in California.
See all interventional pain medicine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 31 | $12,955 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 184 | $5,075 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 110 | $3,226 |
| Oxycodone Hcl | 157 | $2,845 |
| Pregabalin | 83 | $1,932 |
| Tizanidine Hcl | 93 | $1,540 |
| Lidocaine | 32 | $1,466 |
| Morphine Sulfate ErMorphine Sulfate | 63 | $1,414 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 16 | $1,304 |
| Buprenorphine Hcl | 29 | $1,063 |
| Naloxone Hcl | 14 | $1,036 |
| Duloxetine Hcl | 76 | $994 |
| Gabapentin | 75 | $953 |
| Fentanyl | 11 | $853 |
| Morphine Sulfate | 40 | $599 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine Hcl, Morphine Sulfate | $58 | $2,96685 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 188 interventional pain medicine providers in California.
Other interventional pain medicine in la Mesa
- Michael Verdolinla Mesa$563K
- Sheldon JordanSanta Monica$3.1M
- Ezekiel FinkBeverly Hills$2.3M
- Matthew DotyOroville$1.3M
- Tim LeierRancho Mirage$749K
- Pragya GuptaEscondido$647K
- Standiford HelmOrange$476K
- Patrick BuchananCamarillo$453K
- Roy BrownlowSan Diego$452K
- Andrew GermanovichRancho Mirage$408K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.